Berita Kesehatan
Extracorporeal membrane oxygenation for ARDS due to Pneumocystis pneumonia
Kamis, 27 Jun 2019 12:36:02

Klaus StahlHeiko SchenkBenjamin SeeligerOlaf WiesnerJulius J. SchmidtJohann BauersachsTobias WelteChristian KühnAxel HaverichMarius M. HoeperSascha David

European Respiratory Journal 2019; DOI: 10.1183/13993003.00410-2019

Extract

Pneumocystis jirovecii pneumonia (PcP) occurs exclusively in immunocompromised patients. About 50% of PcP is HIV-related, the other half associated with immunosuppression for other reasons [1]. If PcP progresses to an acute respiratory distress syndrome (ARDS) requiring intensive care and invasive mechanical ventilation, the prognosis is generally poor [1] and mortality is about 80% if additional veno-venous extracorporeal membrane oxygenation (VV-ECMO) support is necessary [1]. Despite lack of clear evidence [2], VV-ECMO has become an integral part in the rescue therapy of severe ARDS. Moreover, some centers start VV-ECMO at early time-points in order to rigorously follow (ultra-) protective ventilation strategies [3].

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Stahl has nothing to disclose.

Conflict of interest: Dr. Schenk has nothing to disclose.

Conflict of interest: Dr. Seeliger has nothing to disclose.

Conflict of interest: Dr. Wiesner has nothing to disclose.

Conflict of interest: Dr. Schmidt has nothing to disclose.

Conflict of interest: Dr. Bauersachs has nothing to disclose.

Conflict of interest: Dr. Welte reports personal fees from AstraZeneca, Boehringer, Berlin Chemie, Chiesi, GSK, Novartis, grants from AstraZeneca, Novartis, outside the submitted work.

Conflict of interest: Dr. Kühn has nothing to disclose.

Conflict of interest: Dr. Haverich has nothing to disclose.

Conflict of interest: Dr. Hoeper reports personal fees from Actelion, personal fees from Bayer, personal fees from MSD, personal fees from Pfizer, outside the submitted work.

Conflict of interest: Dr. David has nothing to disclose.